Lexeo Therapeutics, INC 8-K filings

Lexeo Therapeutics announced key business highlights and financial results for Q2 2026, including the initiation of a pivotal trial for LX2006 and FDA RMAT designation for LX2020, with cash runway extending into 2028.

Lexeo Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of Class III Directors and the ratification of KPMG LLP as its independent auditor.

Lexeo Therapeutics announces finalized pivotal trial protocol for LX2006, targeting Friedreich Ataxia cardiomyopathy with a potential Biologics License Application submission in 2028.

Lexeo Therapeutics reported Q1 2026 business highlights and financial results, noting progress in its cardiac genetic medicine pipeline and a cash runway into 2028.

Lexeo Therapeutics, Inc. announced the appointment of Dr. Laura Sepp-Lorenzino to its Board of Directors, effective April 28, 2026.

Lexeo reported $246.6M in cash for runway into 2028, FDA-aligned steps toward a pivotal LX2006 trial, and encouraging ACC data across LX2006 and LX2020.

Lexeo Therapeutics announced Dr. Adler stepped down as Head of Research, transitioning to an advisory role with a compensation package.

Lexeo Therapeutics announced key leadership changes, appointing Jose Manuel Otero as Chief Operating Officer and Narinder P. Bhalla as Chief Medical Officer, while Eric Adler transitions to Myoventive.

Lexeo Therapeutics announced positive interim Phase 1/2 clinical data for LX2020, showing it was well tolerated and demonstrated robust protein expression and reduced arrhythmia burden in PKP2-associated arrhythmogenic cardiomyopathy.

Lexeo Therapeutics announced its third quarter 2025 financial results and significant progress in its cardiac gene therapy pipeline, including regulatory openness for LX2006 and a $154 million equity financing.

Lexeo Therapeutics announced the pricing of a $125 million public offering and a $10 million concurrent private placement, alongside positive clinical updates for its LX2006 and LX2020 gene therapy programs.

Lexeo Therapeutics announced positive interim Phase 1/2 clinical data for LX2006 in Friedreich ataxia cardiomyopathy and progress with the FDA on an accelerated approval pathway.

Lexeo Therapeutics announced Q2 2025 financial results, FDA Breakthrough Therapy designation for LX2006, progress in its clinical pipeline, and a new CFO appointment.

Lexeo Therapeutics, Inc. announced the successful election of Class II Directors and the ratification of KPMG LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Lexeo Therapeutics announced an $80 million private placement of common stock and warrants, extending its cash runway into 2028 to advance its cardiovascular genetic medicine programs.

Lexeo Therapeutics reports positive interim data for LX2006 in Friedreich ataxia cardiomyopathy and LX2020 in PKP2-associated arrhythmogenic cardiomyopathy, along with Q1 2025 financial results.

Lexeo Therapeutics reports positive interim Phase 1/2 clinical data for LX2006 in Friedreich Ataxia cardiomyopathy, showing significant improvements in cardiac biomarkers and frataxin expression, paving the way for a registrational study.

Lexeo Therapeutics reports progress on its cardiovascular genetic medicine programs, including alignment with the FDA on LX2006 and positive early data from the LX2020 trial, alongside its full year 2024 financial results.

Lexeo Therapeutics released a corporate presentation detailing progress in their gene therapy programs for cardiac diseases, including positive initial clinical data and upcoming milestones.

Lexeo Therapeutics has appointed Dr. Kyle Rasbach as its new Chief Financial Officer, effective December 18, 2024, bringing extensive life sciences and financial experience to the company.

Lexeo Therapeutics reports progress across its clinical programs, including FDA alignment on a key development pathway, and appoints a new director to its board.

Lexeo Therapeutics reports positive interim results from its Phase 1/2 study of LX1001, a gene therapy showing promise in treating APOE4-associated Alzheimer's disease by increasing neuroprotective APOE2 expression and reducing tau biomarkers.

Lexeo Therapeutics has updated its corporate presentation, outlining expected data releases for its gene therapy programs targeting cardiovascular diseases and APOE4-associated Alzheimer's disease.

Lexeo Therapeutics reported positive interim data from its Phase 1/2 studies for Friedreich ataxia cardiomyopathy and provided an update on its financial position for the second quarter of 2024.

Lexeo Therapeutics reports positive interim Phase 1/2 clinical data for LX2006, showing significant improvements in cardiac function for patients with Friedreich ataxia cardiomyopathy.

Lexeo Therapeutics has appointed Tim Van Hauwermeiren, CEO of argenx SE, to its board of directors, bringing extensive experience in biotech company building and commercialization.

Lexeo Therapeutics held its 2024 Annual Meeting of Stockholders, where a Class I Director was elected and the appointment of KPMG LLP as the independent auditor was ratified.

Lexeo Therapeutics announced its first quarter 2024 financial results, highlighted by a $95 million equity financing and progress in its gene therapy programs.

Lexeo Therapeutics has secured an exclusive license from Cornell University for gene therapy data related to Friedreich's ataxia cardiomyopathy, aiming to accelerate the development of their drug candidate LX2006.

Lexeo Therapeutics announces that director Bernard Davitian will not seek re-election at the company's 2024 annual meeting.